These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15836868)

  • 21. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.
    Hollander P
    Am J Med; 2007 Feb; 120(2 Suppl 1):S18-28; discussion S29-32. PubMed ID: 17296341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
    Scheen AJ
    J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. End of the line for cannabinoid receptor 1 as an anti-obesity target?
    Jones D
    Nat Rev Drug Discov; 2008 Dec; 7(12):961-2. PubMed ID: 19043439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contribution of CB1 blockade to the management of high-risk abdominal obesity.
    Després JP; Lemieux I; Alméras N
    Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S44-52. PubMed ID: 16570106
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats.
    Janiak P; Poirier B; Bidouard JP; Cadrouvele C; Pierre F; Gouraud L; Barbosa I; Dedio J; Maffrand JP; Le Fur G; O'Connor S; Herbert JM
    Kidney Int; 2007 Dec; 72(11):1345-57. PubMed ID: 17882151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. STRADIVARIUS: a brave trial aimed at clarifying benefits of rimonabant therapy.
    Cardiovasc J Afr; 2008; 19(3):158-9. PubMed ID: 18568179
    [No Abstract]   [Full Text] [Related]  

  • 27. [Pharmacology of cannabinoid receptors].
    Le Fur G; Rinaldi-Carmona M; Barth F; Alexander J
    Bull Acad Natl Med; 2007; 191(4-5):933-8; discussion 938-40. PubMed ID: 18225447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data.
    Bronander KA; Bloch MJ
    Vasc Health Risk Manag; 2007; 3(2):181-90. PubMed ID: 17580728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Acomplia, an essential medication or a "comfort" product?].
    Nau JY
    Rev Med Suisse; 2006 Nov; 2(85):2516. PubMed ID: 17120725
    [No Abstract]   [Full Text] [Related]  

  • 30. [The endocannabinoid system].
    Sudano I; Périat D; Noll G
    Praxis (Bern 1994); 2008 Apr; 97(7):375-80. PubMed ID: 18548817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Positive influence on cardiovascular risk factor by blocking the endocannabinoid system].
    Chatterjee T; Ritz A; Ince H; Nienaber ChA; Rehders TC
    Praxis (Bern 1994); 2008 May; 97(11):613-21. PubMed ID: 18592956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cannabinoids and cardiovascular disease: the outlook for clinical treatments.
    Ashton JC; Smith PF
    Curr Vasc Pharmacol; 2007 Jul; 5(3):175-85. PubMed ID: 17627561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns?
    Pacher P
    Arterioscler Thromb Vasc Biol; 2009 Jan; 29(1):7-9. PubMed ID: 19092136
    [No Abstract]   [Full Text] [Related]  

  • 34. [Blocking cannabinoid receptors. Simultaneous control of overweight and nicotine addiction].
    MMW Fortschr Med; 2004 Mar; 146(10):44. PubMed ID: 15347084
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of rimonabant on weight reduction and cardiovascular risk.
    Astrup A
    Lancet; 2005 Jul 30-Aug 5; 366(9483):368; author reply 369-70. PubMed ID: 16054932
    [No Abstract]   [Full Text] [Related]  

  • 36. [Blocking the endocannabinoid system -- weight reduction and cardiovascular risk management].
    Bramlage P; Böcking W; Kirch W
    Dtsch Med Wochenschr; 2005 Mar; 130(12):665-8. PubMed ID: 15776349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors.
    Tonstad S
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):156-62. PubMed ID: 16487916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic syndrome treatment strategies.
    Fujioka K
    Pharmacotherapy; 2006 Dec; 26(12 Pt 2):222S-226S. PubMed ID: 17125449
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple impacts of rimonabant on cardiometabolic risk and safety addressed at ESC congress, Vienna.
    Cardiovasc J Afr; 2007; 18(5):336-7. PubMed ID: 17985035
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients.
    Lafontan M; Piazza PV; Girard J
    Diabetes Metab; 2007 Apr; 33(2):85-95. PubMed ID: 17418607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.